Skip to main content

Table 2 Maternal characteristics by prenatal opioid agonist treatment for 332 pregnancies

From: Prenatal treatment for opioid dependency: observations from a large inner-city clinic

Characteristic

Mean and standard deviation or number and proportion

Mean difference or risk ratio and 95% CI (adjusted for year of birth)

Buprenorphine (N = 82)

Methadone (N = 245)

Buprenorphine and methadone (N = 5)

Buprenorphine versus methadone

Maternal age (years)

28.1 ± 5.1

27.7 ± 5.1

27.2 ± 3.3

0.76 (−0.55, 2.07)

Year of deliverya

 2009–2010

60 (73.2)

114 (46.5)

3 (60.0)

1.57 (1.30, 1.90)

 2006–2008

22 (26.8)

131 (53.5)

2 (40.0)

1.0

Number of fetuses

 Singleton

80 (97.6)

241 (98.4)

5 (100)

 Twin

2 (2.4)

4 (1.6)

0 (0)

 

 Prenatal care

82 (100)

241 (0.99)

5 (100)

 Gestational age at presentation for care (weeks)

16.4 ± 8.9

17.2 ± 8.9

11.8 ± 8.6

−0.16 (−2.46, 2.13)

 Number of prenatal care visits

11.5 ± 4.7

8.7 ± 4.3

11.6 ± 2.2

3.06 (1.92, 4.20)

 Initial daily dose of opioid agonist therapy (mg)

12.0 ± 6.5

68.3 ± 37.4

12.0 ± 4.0

Stopped agonist therapy during pregnancy

 Yes

2 (2.4)

0 (0)

0 (0)

 No

80 (97.6)

245 (100)

5 (100)

 

Daily dose of opioid agonist therapy at delivery (mg)

15.1 ± 7.5

89.3 ± 41.7

77.0 ± 28.9

Smoked cigarettes

54 (65.9)

164 (66.9)

4 (80.0)

Hepatitis C infected

32 (39.0)

134 (54.7)

4 (80.0)

Prescribed SSRIs

14 (17.1)

38 (15.5)

2 (40.0)

1.01 (0.57, 1.79)

1.0

Prescribed benzodiazepines

14 (17.1)

51 (20.8)

0 (0)

0.81 (0.47, 1.39)

1.0

Prescribed antipsychotics

1 (1.2)

18 (7.4)

0 (0)

0.15 (0.02, 1.12)

1.0

Other prescribed psychiatric medications

9 (11.0)

15 (6.1)

2 (40.0)

1.60 (0.72, 3.60)

1.0

Urine screen

 ≥1

78 (95.1)

233 (95.1)

5 (100)

1.02 (0.95, 1.09)

 None

4 (4.9)

12 (4.9)

0 (0)

1.0

Positive urine screen

 ≥1

31 (39.7)

123 (52.8)

5 (100)

0.74 (0.55, 1.01)

 None

47 (60.3)

220 (47.2)

0 (0)

1.0

Cocaine urine screen

 Positive

5 (6.4)

63 (27.0)

3 (60.0)

0.24 (0.10, 0.57)

 Negative

73 (93.6)

170 (73.0)

2 (40.0)

1.0

Non-prescribed opioid urine screen

 Positive

22 (28.2)

90 (38.6)

5 (100)

0.69 (0.46, 1.02)

 Negative

56 (71.8)

143 (61.4)

0 (0)

1.0

Non-prescribed benzodiazepines urine screen

 Positive

7 (9.0)

18 (7.7)

0 (0)

1.27 (0.54, 2.98)

 Negative

71 (91.0)

215 (92.3)

5 (100)

1.0

Non-prescribed amphetamine urine screen

 Positive

3 (3.9)

7 (3.0)

0 (0)

1.34 (0.34, 5.31)

 Negative

75 (96.1)

226 (97.0)

5 (100)

1.0

Mode of delivery

 Vaginal

55 (67.1)

138 (56.3)

3 (60.0)

1.15 (0.95, 1.39)

 Cesarean section

27 (32.9)

107 (43.7)

2 (40.0)

1.0

Anesthesia during delivery

 Yes

76 (93.8)

209 (90.9)

5 (100)

1.03 (0.96, 1.11)

 No

5 (6.2)

21 (9.1)

0 (0)

1.0

  1. Missing data: Initial daily dose of opioid agonist therapy, three women treated with buprenorphine, six women treated with methadone; Gestational age at first prenatal visit, one woman treated with methadone. Number of prenatal care visits, two women treated with methadone; Smoking, 12 women treated with buprenorphine, 52 women treated with methadone, 1 woman treated with methadone and buprenorphine; Hepatitis C infection, 11 women treated with buprenorphine, 62 women treated with methadone, 1 woman treated with methadone and buprenorphine; Anesthesia, one women treated with buprenorphine, and 15 women treated with methadone
  2. aUnadjusted result